FOSPHENYTOIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fosphenytoin Sodium, and when can generic versions of Fosphenytoin Sodium launch?
Fosphenytoin Sodium is a drug marketed by Am Regent, Amneal, Apotex Inc, Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Mylan Labs Ltd, Sun Pharm, and Wockhardt. and is included in fourteen NDAs.
The generic ingredient in FOSPHENYTOIN SODIUM is fosphenytoin sodium. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fosphenytoin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fosphenytoin Sodium
A generic version of FOSPHENYTOIN SODIUM was approved as fosphenytoin sodium by FRESENIUS KABI USA on August 6th, 2007.
Summary for FOSPHENYTOIN SODIUM
Recent Clinical Trials for FOSPHENYTOIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Nobelpharma | Phase 3 |
Banaras Hindu University | Phase 2 |
Institute of Medical Sciences of the Banaras Hindu University (BHU),India | Phase 2 |